Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion
Get Quartz in your inbox
Free daily briefing on global business news.
Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion
The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included
jetcityimage / Getty Images
Eli Lilly $LLY agreed to acquire Calytrix Bio, a privately held developer of therapies for myeloproliferative neoplasms, for up to $1.5 billion in cash, the company said on Monday.
Under the definitive agreement, Calytrix shareholders could receive up to $1.5 billion, made up of an upfront payment and further payments that depend on clinical and regulatory milestones being met, the company........
